Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 10/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.50 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.43 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8630043 | 1.00 | ITGB3 (0.50) | ITGB3ITGA2BSLC6A5SLC15A2FOLH1 | |
| SCHEMBL7887537 | 1.00 | ITGB3 (0.50) | ITGB3ITGA2BSLC6A5SLC15A2FOLH1 | |
| SCHEMBL7257726 | 0.99 | ITGB3 (0.48) | ITGB3ITGA2BSLC6A5SLC15A2FOLH1 | |
| SCHEMBL7893552 | 0.98 | ITGB3 (0.47) | ITGB3ITGA2BSLC6A5SLC15A2FOLH1 | |
| SCHEMBL26126284 | 0.95 | ITGB3 (0.44) | ITGB3ITGA2BSLC6A5SLC15A2 | |
| SCHEMBL541261 | 0.95 | ITGB3 (0.44) | ITGB3ITGA2BSLC6A5SLC15A2 | |
| SCHEMBL10937318 | 0.95 | ITGB3 (0.44) | ITGB3ITGA2BSLC6A5SLC15A2 | |
| Methoxymethane SCHEMBL2940968 | 0.91 | ITGB3 (0.46) | ITGB3ITGA2BSLC6A5SLC15A2HDAC6 | |
| Carnosine SCHEMBL3904964 | 0.90 | ITGB3 (0.41) | ITGB3ITGA2BSLC6A5SLC15A2 | |
| Carnosine SCHEMBL33768 | 0.90 | ITGB3 (0.41) | ITGB3ITGA2BSLC6A5SLC15A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0972511-B1 | Association of a retinoid with a histidine derivative | OREAL (FR) | 2003-04-09 | — | — | EP | claimed |
| US-6358514-B1 | FOR SKIN AND HAIRCARE | L'OREAL (FR) | 2002-03-19 | — | — | US | claimed |
| EP-0972511-A1 | Association of a retinoid with a histidine derivative | L'OREAL (FR) | 2000-01-19 | — | — | EP | claimed |
| WO-1999047504-A1 | NOVEL HISTIDINE DERIVATIVES PREPARATION METHOD AND USES | L'OREAL (FR) | 1999-09-23 | — | — | WO | claimed |
| EP-1602354-B1 | Use of polyglutamic acid or its salts | MEIJI SEIKA KAISHA (JP) | 2008-11-05 | — | — | EP | disclosed |
| EP-1604647-B1 | Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof | CHISSO CORP (JP) | 2008-05-07 | — | — | EP | disclosed |
| US-20060165636-A1 | Hair treatment composition and hair cosmetic for damaged hair | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-07-27 | — | — | US | disclosed |
| US-20060018867-A1 | Cosmetic composition and production thereof | ICHIMARU PHARCOS CO., LTD | 2006-01-26 | — | — | US | disclosed |
| EP-1604647-A1 | Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof | Ichimaru Pharcos Co., Ltd. (JP) | 2005-12-14 | — | — | EP | disclosed |
| EP-1602354-A1 | HAIR TREATMENT COMPOSITION AND HAIR COSMETIC FOR DAMAGED HAIR | Meiji Seika Kaisha, Ltd. (JP) | 2005-12-07 | — | — | EP | disclosed |
| EP-0972511-B1 | Association of a retinoid with a histidine derivative | OREAL (FR) | 2003-04-09 | — | — | EP | disclosed |
| US-6358514-B1 | FOR SKIN AND HAIRCARE | L'OREAL (FR) | 2002-03-19 | — | — | US | disclosed |
| EP-0972511-A1 | Association of a retinoid with a histidine derivative | L'OREAL (FR) | 2000-01-19 | — | — | EP | disclosed |
| WO-1999047504-A1 | NOVEL HISTIDINE DERIVATIVES PREPARATION METHOD AND USES | L'OREAL (FR) | 1999-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060165636-A1 | Hair treatment composition and hair cosmetic for damaged hair | CUTA, COL14A1, PRKDC | ITGB3 4676/4885ITGA2B 4586/4885SLC6A5 1664/4885 |
| US-20060018867-A1 | Cosmetic composition and production thereof | CUTA, PARG, TYR | ITGB3 3766/4885ITGA2B 3118/4885SLC6A5 3000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.